相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Hyun Cheol Chung et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
Biagio Ricciuti et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
T. K. Owonikoko et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
L. Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
PD-L1 Expression in Small Cell Lung Cancer
Yuto Yasuda et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune checkpoint inhibitors and small cell lung cancer: what's new?
Sabine Schmid et al.
JOURNAL OF THORACIC DISEASE (2018)
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. K. Sabari et al.
ANNALS OF ONCOLOGY (2018)
Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
Daniel C. Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).
Jonathan Wade Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LBA1Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC
D R Gandara et al.
ANNALS OF ONCOLOGY (2018)
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Julie George et al.
CLINICAL CANCER RESEARCH (2017)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.
Matthew David Hellmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S. Diem et al.
BRITISH JOURNAL OF CANCER (2016)
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
PD-L1 expression in small cell neuroendocrine carcinomas
Anne M. Schultheis et al.
EUROPEAN JOURNAL OF CANCER (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer Findings on the Basis of North Central Cancer Treatment Group Trials
Nathan R. Foster et al.
CANCER (2011)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R. Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Paraneoplastic syndromes involving the nervous system
RB Darnell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
C Mascaux et al.
LUNG CANCER (2000)
分享论文
